Skip to Content

Urografin 150 (diatrizoate) Disease Interactions

There are 5 disease interactions with Urografin 150 (diatrizoate):


Radiopaque contrast agents (applies to Urografin 150) pheochromocytoma

Major Potential Hazard, Moderate plausibility.

Administration of radiopaque materials to patients known or suspected of having pheochromocytoma should be performed with extreme caution. If, in the opinion of the physician, the possible benefits of such procedures outweigh the considered risk, the procedures should be performed with the absolute minimum amount of injected radiopaque medium. The blood pressure should be assessed throughout the procedure and measures for treatment of a hypertensive crisis should be available.


Diatrizoate (applies to Urografin 150) congestive heart failure

Moderate Potential Hazard, Moderate plausibility.

Due to the transitory increase in the circulatory osmotic load, injections with urographic agents should be used with caution in patients with congestive heart failure. Such patients should be observed for several hours following the procedure to detect delayed hemodynamic disturbances.


Intravascular contrast agents (applies to Urografin 150) multiple myeloma

Moderate Potential Hazard, Moderate plausibility.

A definite risk exists in the use of intravascular contrast agents in patients who are known to have multiple myeloma. In such cases, anuria has developed resulting in progressive uremia, renal failure and eventually death. Although neither the contrast agent nor dehydration has separately proved to be the cause of anuria in myeloma, it has been speculated that the combination of both may be causative factors. The risk in patients with myeloma is not a contraindication to the procedure; however, partial dehydration in the preparation of these patients for the examination is not recommended since this may predispose to precipitation of myeloma protein in the renal tubules. Myeloma, which occurs most commonly in persons over 40, should be considered before instituting intravascular administration of contrast agents.


Iodinated contrast agents (applies to Urografin 150) myasthenia gravis

Moderate Potential Hazard, Moderate plausibility.

The administration of iodinated contrast media may aggravate the symptoms of myasthenia gravis. Caution is advised when using these agents in patients with this condition.


Iodinated contrast media (applies to Urografin 150) asthma/allergies

Moderate Potential Hazard, Moderate plausibility.

Iodinated contrast media such as ioversol, can cause life-threatening or fatal hypersensitivity reactions including anaphylaxis and anaphylactic shock. Manifestations include respiratory arrest, laryngospasm, bronchospasm, angioedema, and shock. Most severe reactions develop shortly after the start of the injection (e.g. within 1 to 3 minutes), but delayed reactions may occur. There is an increased risk in patients with a history of a previous reaction to contrast agent, and known allergies (i.e., bronchial asthma, drug, or food allergies), and other hypersensitivities. Caution is advised on these patients. Premedication with antihistamines or corticosteroids to avoid or minimize possible allergic reactions may reduce both their incidence and severity.

Urografin 150 (diatrizoate) drug interactions

There are 163 drug interactions with Urografin 150 (diatrizoate)

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.